Takeda Canada released the news  results from its Phase 3b clinical trial, VARSITY, comparing Takeda’s ENTYVIO® (vedolizumab) to AbbVie's HUMIRA® (adalimumab) in patients with moderately-to-severely active ulcerative colitis (UC) who had failed conventional treatments...